Characteristics of people with epilepsy in three Eastern African countries – a pooled analysis

Dominik Stelzle1*, Joyce Kaducu2*, Veronika Schmidt1,3, Tamara M. Welte1,4, Bernard J. Ngowi5,6, William Matuja7, Gabrielle Escheu8, Peter Hauke8, Vivien Richter9, Emilio Ovuga10, Bettina Pfaußer11, Erich Schmutzhard11, Action Amos12, Wendy Harrison13, Luise Keller14* and Andrea S. Winkler1,3*

Abstract

Background: Epilepsy is one of the most common neurological disorders worldwide. Yet, its treatment gap is large in some areas and especially in sub-Saharan Africa data on clinical, radiological and semiological characteristics, as well as on treatment of persons with epilepsy (PWE) are still scarce.

Methods: We pooled data from four cross-sectional studies on epilepsy in eastern Africa. Two studies from Malawi and Uganda were community-based; two studies in Tanzania (urban Dar es Salaam and rural Haydom) were hospital-based. Clinical characteristics of PWE were assessed by the same questionnaire. Additionally, data on treatment were collected and computed tomography (CT) scans were performed.

Results: Overall, 1179 PWE were included in our analysis (581 (49.3%) female, median age 22 years (IQR 15–32 years)). Up to 25% of the patients had focal onset seizures. Those showed a higher rate of remarkable CT scan findings, with especially post-ischaemic and neurocysticercosis-associated lesions, compared to PWE with generalized onset seizures (35.1% vs. 20%). The majority of the patients experienced tonic–clonic seizures (70–85%). Only 67–78% of PWE received anti-seizure medication (ASM) treatment in the community-based studies, mostly monotherapy with phenobarbital, phenytoin or carbamazepine. Yet, underdosage was frequent and a large proportion of PWE received alternative non-ASM treatment consisting of herbal treatment (up to 83%) and/or scarification (up to 20%).

Conclusions: Epilepsy is common in sub-Saharan Africa, often caused by neurocysticercosis or ischaemic strokes. PWE suffer from high seizure rates and subsequent injuries, as well as from socio-economic consequences due to insufficient ASM treatment. This pooled analysis illustrates the need for structural programmes for adequate identification, education, assessment and treatment of PWE in sub-Saharan Africa.

Keywords: Epilepsy, Sub-Saharan Africa, Global health, Treatment gap

Key points

- Epilepsy is common in low-income and middle-income countries and aetiologies seem to differ from high-income countries
- Neurocysticercosis and post-ischaemic lesions are common CT findings among people with epilepsy in eastern Africa
Many people with epilepsy are either not on anti-seizure medication or are under dosed resulting in high seizure frequency.

- Carbamazepine, Phenobarbital, and Phenytoin are commonly used anti-seizure medication whereas Valproic acid is only rarely used.
- Injuries due to epileptic seizures are common in eastern Africa and may reflect the high seizure-related mortality.

**Background**

Epilepsy is affecting approximately 46 million people globally and therefore is one of the most common neurological disorders worldwide [1]. If one accounts for family members and relatives of persons with epilepsy (PWE), whose lives are likewise socially and economically affected, this number will increase considerably. The majority of PWE are suspected to live in low-income and middle-income countries (LMIC) [2]. However, epilepsy prevalence estimates are varying notably, probably due to a wide range of different aetiologies including genetic, environmental and behavioural risk factors. *Taenia solium* neurocysticercosis (NCC) is known to be one of the leading causes of epilepsy in LMIC [3]. However, there is still a large research gap concerning the contribution of other infectious diseases like cerebral malaria, meningitis or HIV/AIDS to the prevalence of epilepsy in low-resource settings. Same applies for the raising burden of cerebrovascular diseases due to the epidemiological transition in many LMIC [4–8].

As neuroimaging, electroencephalography (EEG) or direct observations of epileptic seizures are rare, diagnosis of epilepsy mostly is made based on reports and descriptions of epileptic events by the patients themselves or observers. Consequently, reliable estimates on epilepsy prevalence and causes are difficult to ascertain. Furthermore, other medical conditions like syncope, movement or sleep disorders may be difficult to distinguish from epileptic seizures, especially by non-specialists. Additionally, underreporting may occur due to potential stigma and discrimination of PWE, especially in rural areas [9–11].

Despite cheap and effective anti-seizure medication (ASM) being available, and often being free of charge, access to sustained medical treatment is limited for many people in LMIC [12]. Large treatment gaps were already reported before, i.e. PWE not being treated with ASM or treated with insufficient dosage, resulting in up to more than 60% of PWE in Africa not receiving adequate treatment [13–16]. Reasons are partly patient-related, particularly concerning cultural beliefs and stigma about epilepsy; but also financial constraints from both a patient and a system perspective, or stock-out of ASM play an important role [11, 17, 18].

Knowledge about geographic, demographic, and clinical characteristics, types and frequency of epileptic seizures, relevant co-morbidities as well as the underlying causes of epilepsy is crucial for good clinical practice and appropriate management of PWE as well as adequate planning of resource allocation. That is why this study aimed to pool these factors from four studies on epilepsy in three African countries.

**Methods**

Characteristics and methodology of this pooled analysis have been described elsewhere [19].

In short, the current study was part of a large study that focused on neurocysticercosis in PWE from four study sites of three eastern sub-Saharan African countries. Here we report on the pooled epilepsy data. PWE (*n* = 1179) were examined in-depth including demographic, clinical, semiological (related to epileptic seizures), neuroradiological and therapeutic (related to anti-seizure medication) variables. Two of the four studies were conducted in hospital-based settings in Tanzania (Haydom and Dar es Salam) [3, 20]. The other two studies were community-based; one was conducted in northern Uganda and one in Balaka district in Malawi.

A flowchart of included patients by site is displayed in Fig. 1 and the detailed methodology can be found in the Supplement.

**Evaluation of epilepsy**

All four studies applied the same in-depth epilepsy questionnaire, despite few questions not included in all studies (indicated not applicable [NA] in the tables). Data collection comprised information on demography, seizure history and semiology, pre-existing health conditions, past medical and psychiatric history, perinatal and family history, ASM and neurological examination. CT scanning was performed locally at the different study sites, under supervision of trained clinical stuff. CT reports were all done by the same neuroradiologist (VR) at the Department of Radiology, Technical University of Munich (TUM), Germany.

Semiology of seizure type was categorized according to the 2017 ILAE definition of seizure onset (focal/generalised) [21]. Diagnosis was based on reported semiological characteristics only. Consequently, report of an aura before seizures or an unilateral beginning led to classification as focal onset seizure, whereas lack of these signs led to classification as generalised onset seizure. We additionally used classification according to Winkler et al.
who proposed an epilepsy definition which was created for African settings. For this classification we used all information available (apart from CT scan).

**Statistical analysis**

Presentation of baseline data was done by centre and as total values. For binary values, numbers and proportions are presented; median and interquartile range (IQR) are presented for continuous data. Although screening and examination tools were well comparable between studies, we mostly did not perform statistical testing because of different recruitment procedures and potential selection bias. R version 4.1.1. was used for all analyses.

**Results**

Overall, 2749 PWE were included in the four studies. In the community-based studies, epilepsy prevalence was 1.1% (95%CI 1.0–1.1%) in Malawi and 3.3% (95%CI 3.1–3.4%) in Uganda (Table 1). After exclusion of patients who were not eligible for further clinical work-up, 1179 patients remained. In Tanzania 514 (hospital-based; Dar es Salaam: 302, Haydom: 212), in Malawi 365 (community-based) and in Uganda 300 (community-based). For more details refer to Fig. 1. Of the 1179 PWE, 581 (49.3%) were female, and median age of patients was 22 years (IQR 15 to 32 years). Patients from Malawi were in the median younger (18 years [IQR 12 to 31 years]) than patients in the other three studies. In the urban Dar es Salaam study site, more patients were single than in the other rural study sites. In Haydom and Uganda, around 90% of patients were Christians; in Dar es Salaam and Malawi the percentage was smaller (51% and 58%) and there were proportionally more Muslims included. 941 (80%) of the 1179 patients had a CT scan (Table 1).

**Characteristics and treatment of patients with epilepsy**

Clinical characteristics are presented in Table 2. Median age at first epileptic seizure ranged from 10 to 15 years between the studies. Frequency of seizures varied between the studies. Whilst 77.1% of patients in Haydom had seizures only once a year or less often, this proportion was 4.6% in Malawi, 21.0% in Dar es Salaam and 21.5% in Uganda. Yet, up to 17.5% of PWE (in Malawi) experienced seizures daily to weekly. In Uganda and Malawi, every other PWE had ever experienced injuries during fits. These were mostly tongue bites, bruises or burns. The majority of patients at all sites experienced tonic–clonic seizures (from 70 to 85%; Table 2). According to the ILAE criteria for seizure type, 7.7% of patients in Uganda had focal onset seizures, 20.2% in Dar es Salaam, 21.1% in Malawi and 28.8% in Haydom. However, the vast majority of PWE had generalised onset seizures according to the ILAE criteria. Most PWE had generalised seizures within a specific age range according to the definition by Winkler et al., which represents the category in which least focal onset seizures are assumed [22].

The CT diagnoses of PWE can be found in Table 3; these were most commonly atrophy (8.2%) and post-ischaemic lesions (7.9%). PWE with focal onset seizures more commonly showed focal lesions (e.g. post-ischaemic lesions, NCC or tumours) than PWE

---

**Fig. 1** Flowchart of the patient selection by site
with generalised onset seizures (Table 3). Overall, 728 of 941 (77.4%) CT scans were unremarkable, more among patients with generalised onset seizures than focal onset seizures (80.4% versus 64.9%).

Chronic illnesses were infrequent apart from psychiatric disorders which were reported by 7%, 9% and 17% of patients in rural study sites and 54% of patients in the urban study site (Dar es Salaam). The most common psychiatric disorders were dementia, mental retardation, and psychotic episodes. Every third to fourth patient reported a family member with epilepsy, which in Tanzania (Dar es Salaam/Haydom) mostly was a first-degree family member. In comparison, in Uganda only 13% of patients had first degree family members with epilepsy. In the urban study site (Dar es Salaam), 92% of patients went to school, compared with 64% to 75% of patients at the rural study sites. Especially in Malawi and Uganda, many patients dropped out of school, often because of epilepsy (Table 2).

In the community-based studies less patients received ASM (Malawi: 68%, Uganda: 78%) compared with the hospital-based studies, where 90% (Dar es Salaam) and 99% (Haydom) of PWE were on ASM. Monotherapy with ASM was the most common form, which was present in almost all PWE, whose treatment modalities were

| Table 1 Baseline characteristics of persons with epilepsy from four different studies |
|------------------------------------------|----------|----------|----------|----------|----------|
| Tanzania (Dar es Salaam)                | Tanzania (Haydom) | Malawi   | Uganda   | Overall  |
| Urban (Hospital-based)                  | Rural (Hospital-based) | Rural (Community-based) | Rural (Community-based) | Overall (with CT available) |
| n                                        | 302      | 212      | 365      | 300      | 1179     | 941      |
| Epilepsy prevalence (95%CI)             | 1.1% (1.0–1.3%) | 3.3% (3.1–3.4%) | 80.4%     | 64.9%    |          |          |
| Sex                                      | female   | 160 (53.0) | 104 (49.1) | 189 (51.8) | 128 (42.7) | 581 (49.3) | 460 (48.9) |
|                                          | male     | 142 (47.0) | 108 (50.9) | 176 (48.2) | 172 (57.3) | 598 (50.7) | 481 (51.1) |
| Age group                                | children (< 15 years) | 58 (19.2) | 42 (19.8) | 103 (29.3) | 57 (19.0) | 260 (22.3) | 203 (21.6) |
|                                          | adolescents (15–29 years) | 148 (49.0) | 113 (53.3) | 141 (40.2) | 154 (51.3) | 556 (47.7) | 462 (49.1) |
|                                          | adults (30–49 years) | 73 (24.2) | 38 (17.9) | 77 (21.9) | 61 (20.3) | 249 (20.6) | 194 (20.6) |
| Age in years                             | median (IQR) | 23 [16–32] | 22 [15–30] | 30 [8.5] | 28 [9.3] | 100 (8.6) | 82 (8.7) |
| Marital status                           | single | 232 (76.8) | 126 (59.4) | 232 (63.6) | 58 (19.3) | 648 (54.9) | 226 (24) |
|                                          | married/cohabiting | 54 (17.9) | 81 (38.2) | 92 (25.2) | 55 (18.3) | 282 (23.9) | 51 (5.4) |
|                                          | separated/ divorced/widowed | 14 (4.6) | 5 (2.4) | 38 (10.4) | 24 (8) | 82 (6.9) | 497 (52.8) |
|                                          | unknown | 2 (0.7) | 0 (0) | 3 (0.8) | 163 (54.3) | 168 (14.2) | 167 (17.7) |
| Religion                                  | Christian | 151 (50) | 189 (89.2) | 215 (58.9) | 284 (94.7) | 839 (71.2) | 707 (75.1) |
|                                          | Muslim | 148 (49) | 3 (1.4) | 147 (40.3) | 6 (2.0) | 304 (25.8) | 199 (21.1) |
|                                          | other | 0 (0.0) | 6 (2.8) | 3 (0.8) | 10 (3.3) | 19 (1.6) | 18 (1.9) |
|                                          | unknown | 3 (1.0) | 14 (6.6) | 0 (0.0) | 0 (0.0) | 17 (1.4) | 17 (1.8) |
| Occupation                                | farmer | 0 (0) | 196 (92.5) | 179 (49.0) | 91 (30.3) | 466 (39.5) | 334 (35.5) |
|                                          | professional | 59 (19.5) | 0 (0) | 7 (1.9) | 3 (1) | 69 (5.9) | 66 (7.0) |
|                                          | student | 93 (30.8) | 0 (0) | 103 (28.2) | 0 (0) | 196 (16.6) | 149 (15.8) |
|                                          | trader/business | 3 (1) | 5 (2.4) | 15 (4.1) | 9 (3) | 32 (2.7) | 20 (2.1) |
|                                          | other | 15 (5) | 8 (3.8) | 27 (7.4) | 197 (65.7) | 247 (20.9) | 226 (24.0) |
|                                          | none | 123 (40.7) | 3 (1.4) | 14 (3.8) | 0 (0) | 140 (11.9) | 134 (14.2) |
|                                          | unknown | 9 (3) | 0 (0) | 20 (5.5) | 0 (0) | 29 (2.5) | 12 (1.3) |
| Pork consumption                         | 155 (51.7) | 162 (77.5) | 103 (29) | 213 (71.2) | 637 (54.0) | 568 (61.1) |
| Family pork consumption                  | 184 (61.3) | 87 (41.0) | NA | NA | 271 (52.9) | 271 (52.9) |
| Free roaming pigs living close by        | 23 (7.7) | NA | 58 (16) | 86 (28.8) | 167 (14.2) | 134 (14.8) |
| Latrine use                              | 221 (90.6) | 203 (97.1) | NA | NA | 644 (85.6) | 644 (85.6) |
Table 2  Characteristics of persons with epilepsy from four different studies

|                        | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|------------------------|--------------------------|-------------------|--------|--------|
| n                      | 302                      | 212               | 365    | 300    |
| Loss of consciousness  |                          |                   |        |        |
|                        | 300 (99.3)               | 210 (99.1)        | 359 (98.4) | 287 (95.7) |
| Motor activity          |                          |                   |        |        |
| tonic–clonic            | 211 (69.9)               | 178 (84.0)        | 311 (85.2) | 213 (71.0) |
| tonic                   | 31 (10.3)                | 25 (11.8)         | 21 (5.7) | 58 (19.3) |
| clonic                  | 12 (4.0)                 | 9 (4.2)           | 25 (6.8) | 15 (5.0) |
| myoclonic               | 0                       | 0                 | 0       | 5 (1.7) |
| eye rolling/teeth grinding only | 19 (6.3)         | 0                 | 3 (0.8) | 9 (3.0) |
| no movements at all     | 29 (9.6)                 | 0                 | 5 (1.4) | 0      |
| Motor activity: side of body |                       |                   |        |        |
| bilateral               | 239 (79.9)               | 179 (84.4)        | 249 (75.9) | 283 (94.3) |
| unilateral              | 31 (10.4)                | 33 (15.6)         | 74 (22.6) | 17 (5.7) |
| none                    | 29 (9.7)                 | 0                 | 5 (1.5) | 0      |
| Information missing     | 3                        | 3                 | 37      | 0      |
| Other signs observed (froth from the mouth, urine/stool incontinence) | 246 (81.5) | 199 (93.9) | 323 (88.5) | 287 (95.7) |
| Injuries during seizures|                          |                   |        |        |
| face/head               | 22/46 (47.8)             | 29/82 (35.4)      | 83/177 (46.9) | 94/149 (63.1) |
| thorax                  | 1/46 (2.2)               | 3/82 (3.7)        | 49/177 (27.7) | 7/149 (4.7) |
| limbs                   | 16/46 (34.8)             | 58/82 (70.7)      | 45/177 (25.4) | 81/149 (54.4) |
| Information missing     | 10                       | 4                 | 27      | 1      |
| Treatment for injuries  |                          |                   |        |        |
| operation               | 3/31 (9.7)               | NA                | 1/22 (4.5) | 3/105 (2.9) |
| stitching               | 4/31 (12.9)              | NA                | 0/22    | 0/105 |
| dressing                | 27/31 (87.1)             | NA                | 20/22 (90.9) | 81/105 (77.1) |
| medication              | 4/31 (12.9)              | NA                | 15/22 (68.2) | 14/105 (13.3) |
| other                   | 1/31 (3.2)               | NA                | 0/22    | 7/105 (6.7) |
| Information missing     | 3                        | NA                | 34      | 0      |
| Reorientation after seizures |                       |                   |        |        |
| Age seizures started (years) | 15 (11–22)               | 15 (11–23)        | 10 (6–20) | 14 (11–23) |
|                         | 222 (74.0)               | 152 (72.0)        | 237 (77.5) | 218 (72.7) |
| Frequency of seizures   |                          |                   |        |        |
| daily to weekly         | 44 (14.9)                | 0                 | 57 (17.5) | 9 (4.1) |
| weekly to monthly       | 31 (10.5)                | 4 (1.9)           | 123 (37.7) | 18 (8.2) |
| monthly to yearly       | 158 (53.6)               | 44 (21.0)         | 131 (40.2) | 145 (66.2) |
| yearly or less often    | 62 (21.0)                | 162 (77.1)        | 15 (4.6) | 47 (21.5) |
| Time since last seizure |                          |                   |        |        |
| < 1 month               | 169 (56.5)               | 62 (29.5)         | NA      | 10 (3.4) |
| 1–3 months              | 82 (27.4)                | 41 (19.5)         | NA      | 5 (1.7) |
| 3–12 months             | 42 (14.0)                | 36 (17.1)         | NA      | 20 (6.8) |
| 1–2 years               | 3 (1.0)                  | 27 (12.9)         | NA      | 69 (23.6) |
| > 2 years               | 3 (1.0)                  | 44 (21.0)         | NA      | 188 (64.4) |
| Occurrence of seizures  |                          |                   |        |        |
| anytime                 | 208 (69.3)               | 42 (24.6)         | 115 (31.8) | 163 (54.3) |
| daytime                 | 54 (18.0)                | 25 (14.6)         | 119 (32.9) | 77 (25.7) |
| evening/night           | 6 (2.0)                  | 47 (27.5)         | 32 (8.8) | 40 (13.3) |
| night while asleep      | 32 (10.7)                | 57 (33.3)         | 96 (26.5) | 20 (6.7) |
A combination therapy was given to 11.6% and 3.1% of PWE in Dar es Salaam and Malawi, respectively (Table 4). The type of ASM varied according to availability, with carbamazepine being used by the majority of PWE in Tanzania (both Haydom and Dar es Salaam), phenytoin in Uganda and phenobarbital in Malawi. Information on treatment with ASM in the past was available for Dar es Salaam and Uganda only, with prior ASM in

| Precipitants before seizures | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|-----------------------------|--------------------------|-------------------|--------|--------|
| alcohol                     | 0/89                     | 15/114 (13.2)     | 5/31   | 0/88   |
| fever                       | 13/89 (14.6)             | 30/114 (26.3)     | 16/31 (51.6) | 28/88 (31.8) |
| stress/emotional stimuli     | 14/89 (15.7)             | 18/114 (15.8)     | 2/31 (6.5) | 32/88 (36.4) |
| lack of sleep               | 59/89 (66.3)             | 0/114             | 2/31 (6.5) | 5/88 (5.7)  |
| other                       | 9/89 (10.1)              | 62/114 (54.4)     | 6/31 (19.4) | 23/88 (26.1) |

| History of febrile seizures | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|-----------------------------|--------------------------|-------------------|--------|--------|
| absent                      | 106 (35.7)               | 16 (7.6)          | 177 (48.4) | 47 (15.7)  |
| Past medical history        | 7 (2.3)                  | NA                | 37 (10.1) | 33 (11.1) |
| metabolic/cardiovascular    | 3/7 (42.9)               | NA                | 3/37 (8.1) | 2/33 (6.1) |
| respiratory                 | 1/7 (14.3)               | NA                | 10/37 (27.0) | 4/33 (12.1) |
| infectious                  | 3/7 (42.9)               | NA                | 19/37 (51.4) | 23/33 (69.7) |
| other                       | 0/7                      | NA                | 5/37 (13.5) | 4/33 (12.1) |

| Hospital admission          | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|-----------------------------|--------------------------|-------------------|--------|--------|
| absent                      | 97 (32.4)                | 145 (68.4)        | 139 (38.1) | 118 (39.3) |
| Past psychiatric history    | 162 (53.6)               | 18 (8.5)          | 62 (17.0) | 20 (6.7)  |
| psychosis                   | 72/162 (44.4)            | 0/18              | 17/62 (27.4) | 6/20 (30.0) |
| depression                  | 13/162 (8.0)             | 0/18              | 2/62 (3.2) | 7/20 (35.0) |
| behavioural problems        | 19/162 (11.7)            | 4/18              | 22/62 (35.5) | 3/20 (15.0) |
| dementia                    | 49/162 (30.2)            | 0/18              | 1/62 (1.6) | 2/20 (10.0) |
| mental retardation          | 33/162 (20.4)            | 16/18 (9.8)       | 29/62 (46.8) | 14/20 (70.0) |

| Family history of epilepsy  | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|-----------------------------|--------------------------|-------------------|--------|--------|
| absent                      | 101 (34.1)               | 57 (26.9)         | 107 (29.3) | 88 (29.3)  |
| Degree family member        | first degree             | 47/100 (47.0)     | 39/57 (68.4) | 43/101 (42.6) |
|                             | second degree            | 53/100 (53.0)     | 18/57 (31.6) | 58/101 (57.4) |
| missing                     | 1                        | 0                 | 0      | 2      |
| Mother not healthy during pregnancy | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
| absent                      | 31 (12.0)                | 5 (2.4)           | 15 (4.1) | 9 (3.0)  |
| Schooling                   | 275 (91.7)               | 143 (67.5)        | 273 (74.8) | 192 (64.0) |
| Drop-out of school          | 55 (20.1)                | 59 (27.8)         | 162 (44.4) | 118 (61.5) |
| Focal neurological signs on examination | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
| absent                      | 23 (7.8)                 | NA                | 31 (8.3) | 0      |
| Diagnosis ILAE              | generalised onset        | 240 (79.5)        | 149 (70.3) | 288 (78.9) |
|                             | focal onset              | 61 (20.2)         | 61 (28.8) | 77 (21.1) |
|                             | unclassified             | 1 (0.3)           | 2 (0.9)  | 0      | 0      |
| Diagnosis Winkler et al.21  | gen. seizures within a specific age range | 175 (57.9) | 119 (56.1) | 109 (29.9) |
|                             | gen. seizures outside specific age range | 47 (15.6) | 30 (14.2) | 152 (41.6) |
|                             | gen. seizures with diffuse brain damage | 18 (6.0) | 14 (6.6) | 47 (12.9) |
|                             | gen. seizures with focal signs | 57 (18.9) | 47 (22.2) | 45 (12.3) |
|                             | simple partial seizures  | 2 (0.7)           | 0        | 8 (2.2)  |
|                             | complex partial seizures | 2 (0.7)           | 0        | 4 (1.1)  | 0      | 0      |

| Degree of PWE               | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|-----------------------------|--------------------------|-------------------|--------|--------|
| 1                           | 26 (8.7)                 | 14 (6.6)          | 22 (6.0) | 7 (2.2)  |
| 2                           | 165 (54.9)               | 108 (49.1)        | 157 (42.3) | 91 (30.6) |
| 3                           | 99 (32.6)                | 97 (43.4)         | 209 (55.7) | 70 (23.8) |

| HLA-DRB1                   | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|---------------------------|--------------------------|-------------------|--------|--------|
| B10                        | 68 (22.6)                | 42 (19.1)         | 125 (33.6) | 62 (21.4) |
| B12                        | 9 (3.0)                  | 5 (2.3)           | 28 (7.4) | 11 (3.8) |
| B13                        | 12 (4.1)                 | 7 (3.2)           | 20 (5.3) | 10 (3.5) |
| B14                        | 20 (6.7)                 | 15 (6.8)          | 41 (10.9) | 24 (8.5) |
| B15                        | 1 (0.3)                  | 0                 | 0       | 0      |
| B16                        | 1 (0.3)                  | 1 (0.5)           | 0       | 0      |

| HLA-DQB1                   | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|---------------------------|--------------------------|-------------------|--------|--------|
| B1                          | 50 (16.4)                | 32 (14.5)         | 67 (17.9) | 30 (10.6) |
| B2                          | 9 (3.0)                  | 6 (2.7)           | 16 (4.3) | 6 (2.1)  |
| B3                          | 13 (4.4)                 | 8 (3.6)           | 27 (7.2) | 10 (3.5) |
| B4                          | 9 (3.0)                  | 5 (2.3)           | 20 (5.3) | 10 (3.5) |
| B5                          | 1 (0.3)                  | 1 (0.5)           | 0       | 0      |
| B6                          | 1 (0.3)                  | 1 (0.5)           | 0       | 0      |

recorded.
27.2% and 10.3% of the patients, respectively. The most frequent cause for a change in ASM was not stock-out of medication but none-response to treatment and side-effects, mostly tiredness and/or dizziness (Table 4). Based on data from Haydom and Malawi where exact dosage for PWE on monotherapy was available, most PWE who were treated with phenobarbital, received a daily dose of 60 mg or less (38/53 (72%) in Haydom and 73/164 (45%) in Malawi). Furthermore, in Haydom 71/156 (45%) PWE who were treated with carbamazepine received 400 mg or less per day (Appendix Table 3).

In all three countries, a substantial proportion of patients received alternative non-ASM treatment. In Malawi five out of six patients received or had received herbal treatment for their seizures, and in Tanzania every fifth patient had scaffolding being performed as a cure for epileptic seizures.

### Table 3  CT findings of persons with epilepsy, by type of seizure onset

|                      | Overall (n = 941); n (%) | Focal onset seizures (n = 168); n (%) | Generalised onset seizures (n = 771); n (%) | Unclassified seizures (n = 2); n (%) |
|----------------------|--------------------------|---------------------------------------|--------------------------------------------|-------------------------------------|
| Atrophy              | 77 (8.2)                 | 10 (6.0)                              | 67 (8.7)                                   | 0 (0)                               |
| Hydrocephalus        | 7 (0.7)                  | 2 (1.2)                               | 5 (0.6)                                    | 0 (0)                               |
| Post-ischaemic lesion| 74 (7.9)                 | 18 (10.7)                             | 56 (7.3)                                   | 0 (0)                               |
| Post-haemorrhagic lesion | 4 (0.4)              | 0 (0)                                 | 4 (0.5)                                    | 0 (0)                               |
| Traumatic lesion     | 3 (0.3)                  | 3 (1.8)                               | 0 (0)                                      | 0 (0)                               |
| Tumorous lesion      | 7 (0.7)                  | 3 (1.8)                               | 4 (0.5)                                    | 0 (0)                               |
| NCC                  | 70 (7.4)                 | 16 (9.5)                              | 54 (7)                                     | 0 (0)                               |
| Other                | 55 (5.8)                 | 19 (11.3)                             | 36 (4.7)                                   | 0 (0)                               |
| Unremarkable         | 728 (77.4)               | 109 (64.9)                            | 617 (80)                                   | 2 (100)                             |

*More than one category could be selected

### Table 4  Treatment of persons with epilepsy from four different studies

|                      | Tanzania (Dar es Salaam) | Tanzania (Haydom) | Malawi | Uganda |
|----------------------|--------------------------|-------------------|--------|--------|
| N                    | 302                      | 212               | 365    | 300    |
| ASM                  | 270 (89.7)               | 209 (98.6)        | 248 (67.9) | 233 (77.7) |
| ASM type             |                          |                   |        |        |
| Carbamazepine        | 243/268 (90.7)           | 209/209 (100)     | 222/229 (96.9) | 233/233 (100) |
| Phenobarbital        | 134/268 (50.0)           | 156/209 (74.6)    | 7/229 (3.1) | 31/233 (13.3) |
| Phenytoin            | 103/268 (38.4)           | 53/209 (25.4)     | 201/229 (87.8) | 55/233 (23.6) |
| Valproic acid        | 2/268 (0.7)              | 0/209              | 14/229 (6.1) | 147/233 (63.1) |
| Combination therapy  | 4/268 (1.5)              | 0/209              | 0/229   | 0/233  |
| Carbamazepine, phenobarbital | 25/268 (9.3) | 0/209 | 7/229 (3.1) | 0/233 |
| Carbamazepine, phenytoin | 13/268 (4.9)          | 0/209              | 0/229   | 0/233  |
| Carbamazepine, valproic acid | 4/268 (1.5)            | 0/209              | 2/229 (0.9) | 0/233  |
| Pheno/barbital, gabapentin | 1/268 (0.4)            | 0/209              | 0/229   | 0/233  |
| Pheno/barbital, phenytoin | 6/268 (2.2)            | 0/209              | 5/229 (2.2) | 0/233  |
| Missing/unknown      | 2                       | 0                  | 19      | 0      |
| Ever treated with other ASM | 78 (27.2)              | NA                 | NA      | 31 (10.3) |
| Reason for changing ASM |                       |                   |        |        |
| No response          | 92/24 (37.5)             | NA                 | NA      | 17/31 (54.8) |
| Side effects         | 8/24 (33.3)              | NA                 | NA      | 0/31   |
| Stock-out            | 2/24 (8.3)               | NA                 | NA      | 5/31 (16.1) |
| Other                | 5/24 (20.8)              | NA                 | NA      | 9/31 (29.0) |
| Missing              | 54                      | NA                 | NA      | 0      |
| Herbal treatment     | 159 (53.5)               | 105 (49.5)         | 304 (83.2) | 108 (36.0) |
| Scarification        | 56 (19.2)                | 43 (20.3)          | 33 (9.0) | 10 (3.3) |

ASM Anti-seizure medication
Discussion

In this study, we pooled the results of four studies on epilepsy in eastern Africa to describe the demographic, clinical, semiological, and neuroradiological characteristics, as well as treatment of PWE.

In the two community-based studies (Malawi and Uganda), a screening of people living in the target area was conducted first, comprising more than 100,000 people. Then, screen positives were seen by a neurologist to confirm diagnosis. Lifetime epilepsy prevalence reported in Malawi (1.1% [1.0–1.3%]) and Uganda (3.3% [3.1–3.4%]) were comparable, yet slightly higher than those from a previously published meta-analysis, which found a pooled lifetime prevalence of 0.7% (0.6–0.9%) for epilepsy in eastern Africa [23]. This could be due to our screening questionnaire, which may also have captured more patients with focal onset seizures, which are often not captured at all. Another explanation could be a higher prevalence of risk factors in our cohorts, e.g. NCC. In addition, other studies previously have reported even higher lifetime prevalence estimates for epilepsy of up to 8% [24, 25].

In general, studies estimate that in LMIC around 50% of PWE have secondary epilepsy [11]. In our study, we found a large proportion of patients with seizure onset after adolescence which may indicate a predominance of secondary epilepsy. Unfortunately, we were not able to assess the exact proportion of persons with secondary epilepsy in our study. On the one hand because not many patients showed remarkable findings on CT scan, and for those who did, the temporal association could not be established. On the other hand, patients with obvious traumatic brain injury or perinatal hypoxic brain injury were excluded from further work-up due to study protocol, so that (CT) data on these aetiologies are not representative and most likely vastly underrepresented.

Nevertheless, CT data of almost 950 PWE were available, which to our knowledge represents the largest and most detailed analysis in sub-Saharan Africa. The rate of remarkable CT scan findings was highest in patients with focal onset seizures. Most common findings were neurocysticercosis-associated lesions, but interestingly, an even higher proportion of post-ischaemic lesions could be observed. This finding indicates that cerebrovascular events and post-stroke epilepsy have to be considered as an emerging aetiology for epilepsy in sub-Saharan Africa.

Another frequent CT pathology was cerebral atrophy, which is a common finding in PWE, but the significance and aetiology is hard to determine [26]. The rate of this pathology was higher in patients with general onset seizures, which is also known from previous studies, where patients with idiopathic generalised and genetic seizure syndromes showed diffuse and wide-spread alterations of brain morphology [26–28]. Detailed MRI analyses in these patients sometimes also reveal (wide-spread) cerebral malformations such as lissencephaly with pachygyria or microgyria potentially causing both focal and generalised seizures [29]. Further imaging studies in LMIC are needed to characterize the prevalence and significance of these findings.

The majority of PWE in the four studies had generalised onset seizures according to the ILAE criteria. In this analysis, we also assessed seizures according to the classification by Winkler et al. [22], which looks at epileptic seizures in low-resource settings in a more nuanced way, according to local contexts and needs, and tries to imply information on aetiologies and epilepsy syndromes based on seizure type and occurrence without accessory diagnostic. According to that adjusted classification by Winkler et al., most PWE with generalised seizure onset had generalised seizures within a specific age range, which represents the category in which a possible genetic background can be assumed. PWE of this group are suspected to suffer from idiopathic generalised epilepsies in a large proportion of cases. Consequently, our data suggest that despite a known high prevalence of risk factors for secondary epilepsy and previously reported high prevalence of focal epilepsies [30], genetic and idiopathic epilepsy syndromes also seem to play an important role in LMIC. This finding is of note, although a proportion of 30 to 58% among PWE might represent a certain overestimation in our study due to exclusion criteria for some types of secondary epilepsy as mentioned above. Nevertheless, as genetic origins are various and investigations in such a large and diverse cohort could reveal valuable results for both low-income and high-income countries, our results support the view, that it could be the time for initiating genetic epilepsy research in Africa [31].

Despite a certain proportion of PWE with focal onset seizures in our analysis, most seizures were accompanied by a loss of consciousness and resulted in tonic–clonic seizures. Additionally, injuries during seizures were frequently observed, with a rate of up to 56% in the community-based studies. This is much higher than studies in high-income countries suggest [32, 33] and also is a possible explanation for high epilepsy-associated mortality rates in LMIC [34].

This lack of seizure control may display a lack in adequate ASM therapy. ASM treatment concerning both type and dosage differed substantially between and within countries. In Malawi and Uganda, phenobarbital and phenytin were almost the only ASM prescribed; they were also still very common in Tanzania. In Tanzania, however, the majority of patients was treated with carbamazepine. Valproic acid was basically not available in any of the countries. These findings display the common picture of ASM treatment status in sub-Saharan Africa [35]. These
findings, however, are not only limited to LMIC but can also be observed in high-income countries [36]. Treatment choice in Africa very often depends on availability and cost of treatment and phenobarbital/phenytoin are often cheaper than carbamazepine or valproic acid [17]. Even though ASM are widely available, supply chain is often not sustained which results in stock-outs of medication [17, 37]. Nevertheless, stock-out of medication was not the main reason for changing ASM, but inadequate treatment effect and side-effects. Phenobarbital, in particular, is now rarely prescribed in high-income countries due to its relatively strong side effects and has been replaced by newer ASM [38]. Yet, it is still recommended by the World Health Organization (WHO) as first-line treatment in LMIC because of its cost advantage and broad spectrum of activity [35, 39]. Nevertheless, even in low-resource settings, phenobarbital has a higher risk to be withdrawn due to side-effects than carbamazepine, phenytoin, or valproic acid [39–41].

We found a quite large proportion of patients who had epileptic seizures more often than monthly, especially in the community-based studies, possibly reflecting the lower rates of ASM treatment compared to the hospital-based settings. However, we also found high frequencies of seizures even in patients receiving ASM, which may be due to barriers to accessing healthcare services, supply shortages, or the cost of ASM (mainly to hospitals and sometimes to patients, although ASM are often available free of charge), but also due to underdosage of ASM, which was common in our study. A large part of PWE in our pooled analysis received ≤ 60 mg phenobarbital or ≤ 400 mg carbamazepine per day.

Interestingly, seizure control varied considerably even among the two hospital-based studies, although both showed high treatment rates and treatment with carbamazepine was available. Haydom in rural Tanzania had a high proportion of patients with seizures only yearly or even less often, and no patients with seizures more frequent than monthly, despite underdosage was present in a certain proportion of patients. In contrast, PWE in urban Dar es Salaam showed high seizure rates, comparable to the community-based settings. This could be a result of the study settings, as PWE in Haydom were primarily recruited by a doctor and invited to follow-up visits in the clinic, probably getting access to ASM for the first time in some cases, resulting in good treatment effect, whereas patients in Dar es Salaam were recruited directly from the clinic. One could suspect a high proportion of patients with regular clinic visits due to difficulties to reach seizure control. This might be also reflected by the fact that this was the study site with the highest number of PWE receiving a combination therapy and having a history of prior change in ASM treatment. More studies comparing rural and urban healthcare settings are needed to assess the possible differences and contributing factors.

Many PWE across studies also received alternative treatment for their seizures. This shows the still very prevalent disbelieves about epilepsy as supernatural or witchcraft. In many regions of Africa, PWE are still being stigmatized which makes it difficult to analyse community-based prevalence and which may be the cause of the prevalent undertreatment of PWE.

Epilepsy has a big impact on social life as shown by the fact that many PWE dropped out of school, especially in Malawi and Uganda. In contrast, > 90% of PWE went to school in urban Dar es Salaam despite inadequate seizure control. One could hypothesize that disbelieves and stigmatization is less frequent in urban areas, although alternative non-ASM treatments were equally present in this group.

We report a rather large proportion of PWE who suffer from psychiatric disorders. Studies estimate that up to 50% of all PWE suffer from mental disorders, most commonly from depression, anxiety or dementia [42–45]. This proportion, however, is likely an overestimation as phenomena during seizures may be mischaracterized as mood disorders [46]. Those studies were mainly conducted in high-income countries, and only one was from Sierra Leone. For sub-Saharan Africa, data are still scarce. In our analysis, the proportion of patients with psychiatric disorders differed substantially between studies, which may be due to different assessors, as the questionnaire was the same across countries. Interestingly, prevalence of psychiatric disorders was highest in the urban study site of Dar es Salaam. Differences in education and work as well as different degrees of stigmatization of psychiatric disorders may be a possible explanation. In the four studies, only a small proportion of patients suffered from chronic diseases other than psychiatric illnesses, which is not unusual in sub-Sahara Africa, mostly because diseases can be diagnosed with less certainty.

**Strengths and limitations**

This pooled collection of demographic, clinical, semiological, neuroradiological and therapeutic data on PWE in three countries of East Africa is exceptional and represents sustained work of over 10 years. We give data on epilepsy prevalence proportions derived from two large community-based studies, including screening of over 100,000 people, and describe the different characteristics and treatment of nearly 1200 PWE including CT examinations in almost 950 cases, which is unique within the sub-Saharan African setting.

Consequently, this study represents an important piece of work and adds substantially to the body of literature on epilepsy globally, and specifically to the evaluation and understanding of the burden of epilepsy and the
persisting treatment gaps in sub-Saharan Africa. This has great policy relevance, not only for the respective countries, i.e. Tanzania, Uganda and Malawi, but also at a global level, considering both, the burden of epilepsy, and the growing burden of neurological disorders in LMIC in general [47, 48]. In addition, results from the present analysis may also support the WHO Intersectoral Global Action Plan on Epilepsy and other Neurological Disorders which is currently being drafted [19].

However, our analysis also suffers from several limitations. First, examinations were performed by different personnel and translation of the questionnaire to different languages had to be conducted. This may have influenced the results. Nevertheless, studies applied the same approach to history taking and investigations for the diagnosis of epilepsy. Consequently, the data we focused on in our analyses, such as demographic factors or data on seizure onset and frequency were probably less affected.

As all scans underwent examination by the same radiologist (VR), we consider CT findings reliable and comparable among cohorts. Nevertheless, CT machines and quality of CT scans at different study sites varied considerably and are not comparable to high-income settings. Thus, CT findings may not be as accurate as desired. Additionally, MRI imaging for a more detailed assessment was basically not available.

Due to the studies’ NCC specific settings, investigations focused on evaluation of cryptogenic focal epilepsy and excluded e.g. patients with known traumatic brain injury, leading to a possible overestimation of non-focal epilepsies. A broader approach might have given a more detailed insight in epilepsy aetiologies.

In terms of seizure semiology, we did not assess focal onset signs and symptoms in detail, and therefore were not able to evaluate data with regard to possible epilepsy locations and syndromes such as e.g. temporal lobe epilepsy. Future analyses should give details on awareness during focal seizures, as well as on quality of non-motor symptoms, e.g. autonomic, sensory, cognitive, and emotional symptoms respectively. Additionally, as not all patients were assessed by neurologists, some focal (onset) signs or uncommon seizure semiologies might have been missed in our studies, contributing to a potential under-estimation of focal epilepsies. As accessory diagnostics are limited in LMIC settings, a distinctive and precise history taking might be the best chance to get a more detailed picture of possible epilepsy syndromes and aetiologies.

Another limitation of our study was the mix of hospital-based and community-based studies in our pooled analysis, which probably lead to heterogeneous patient cohorts and occurring selection bias as discussed above.

Nevertheless, if one is aware of the possible problems, this heterogeneity also offers the possibility to observe and analyse the possible differences of study population characteristics. Nevertheless, stigma and only slight signs/symptoms might have influenced the recruitment process in the community-based studies [9]. We tried to constantly indicate the differences between hospital-based and community-based studies throughout our manuscript and therefore consider this pooled analysis appropriate and valuable.

**Conclusion**

In this large and comprehensive study, data on demographic, semiological, clinical, neuroradiological and therapeutic findings of four studies among PWE in eastern Africa were pooled. Overall, epilepsy is common in sub-Saharan Africa and PWE suffer from high seizure rates and subsequent injuries as well as from socio-economic consequences, such as drop out from school. ASM treatment rates are rather low, especially in rural areas, and underdosage is common. Secondary epilepsy plays an important role with CT imaging revealing both, neurocysticercosis-associated and post-ischaemic lesions as the main findings in our study setting. Nevertheless, a large proportion of PWE can also be assumed to suffer from genetic epilepsy syndromes, although study setting might have overestimated this group.

This pooled analysis contributes to the evaluation and understanding of the burden of epilepsy and the persisting treatment gap in sub-Saharan Africa. Our results demonstrate the need of structural programmes, addressing both, acquisition of material resources and transfer of expert knowledge, for adequate identification, education, and treatment of PWE.

**Abbreviations**
PWE: Persons with epilepsy; CT: Computed tomography; IQR: Interquartile range; NCC: Neurocysticercosis; ASM: Anti-seizure medication; LMIC: Low-income and middle-income countries; MRI: Magnetic resonance imaging; WHO: World Health Organization.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12883-022-02813-z.

**Additional file 1:** Appendix Information 1. Methodology of the included studies. Appendix information 2. Ethical clearance obtained. Appendix Table 1. Epilepsy screening questionnaire Malawi. Appendix Table 2. Epilepsy screening questionnaire Uganda. Appendix Table 3. Type and dosage of ASM among patients treated with monotherapy.

**Acknowledgements**
The authors thankfully acknowledge all study participants enrolled in this study for their great cooperation and patience during the long examination days. We are also grateful to the many local colleagues, be it doctors, nurses
or technicians, for their ongoing support in caring for the many patients and supporting us with the different research studies.

Authors' contributions
DS, ASW designed the study, JK, VS, WM, GE, PH, EO, BP, AA, LK collected the data, DS designed the analysis plan and analysed the data, DS, TMW wrote the manuscript; ASW supervised the project, DS, JK, VS, TMW, BJN, WM, GE, PH, VR, EO, BP, ES, AA, WH, LK and ASW reviewed and approved the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This study was funded by the DFG (German Research Foundation) within the research grant (WI 3427/1-1) “Neurocytosis in sub-Saharan Africa” and by the Bill and Melinda Gates Foundation within the research grant (1017886) “Integrated Control of Cysticercosis in sub-Saharan Africa”. The funders had no role in the detailed study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available because further publications are still being analysed from the data. However, data are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
For all studies, local ethics approval was obtained in the respective study country and in Germany (where appropriate). The details on ethical clearance can be found in the Supplement. All participants gave informed consent to the studies. No further ethics approval was necessary for the secondary data analysis. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest.

Author details
1 Center for Global Health, Department of Neurology, School of Medicine, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany. 2 Ministry of Health, Kampala, Republic of Uganda. 3 Centre for Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway. 4 Department of Neurology, University Hospital Erlangen, Erlangen, Germany. 5 National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania. 6 University of Dar es Salaam, Mbeya College of Health and Allied Sciences, Mbeya, Tanzania. 7 Department of Neurology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 8 Department of Neurology, Klinikum Ostallgäu-Kaufbeuren, Kaufbeuren, Germany. 9 Department of Radiology, University Hospital Tuebingen, Tuebingen, Germany. 10 Department of Mental Health, University of Gulu, Gulu, Uganda. 11 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. 12 National Epilepsy Association Malawi, International Bureau of Epilepsy, Lilongwe, Malawi. 13 Department of Infectious Disease Epidemiology, Imperial College London, London, UK. 14 Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany.

Received: 15 April 2022 Accepted: 20 July 2022 Published online: 26 August 2022

References
1. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:357–75. https://doi.org/10.1016/s1474-4422(18)30454-x.
2. Institute for Health Metrics and Evaluation (IHME) University of Washington. Global Burden of Disease Results Tool. https://vizhub.healthdata.org/gbd-results/. Accessed 5 Feb 2020.
3. Winkler AS, Blöcher J, Auer H, Gotwald T, Matuja W, Schmutzhard E. Epilepsy and neurocysticercosis in rural Tanzania-An imaging study. Epilepsia. 2009;50:987–93. https://doi.org/10.1111/j.1528-1167.2008.01867.x.
4. Kellinghaus C, Engelbrin C, Kovac S, et al. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008;17:27–33. https://doi.org/10.1016/j.seizure.2007.05.017.
5. Annegers JF, Hauser WA, Beghi E, Nicolosi A, Kurland LT. The risk of unprovoked seizures after encephalitis and meningitis. Neurology. 1988;38:1407–10. https://doi.org/10.1212/wnl.38.2.1407.
6. Ngoungou EB, Peux PM. Cerebral malaria and epilepsy. Epilepsia. 2008;49(Suppl 6):19–24. https://doi.org/10.15281/1528-1167.2008.01752.x.
7. Ngoungou EB, Koko J, Druet-Cabanac M, et al. Cerebral malaria and sequelar epilepsy: first matched case-control study in Gabon. Epilepsia. 2006;47:2147–53. https://doi.org/10.1111/j.1528-1167.2006.00890.x.
8. Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990;323:1651–7. https://doi.org/10.1056/NEJM1990121332312402.
9. Mushli D, Hunter E, Mutyana C, Mshana G, Aris E, Walker B. Social-cultural aspects of epilepsy in Kilimanjaro Region, Tanzania: knowledge and experience among patients and carers. Epilepsy Behav. 2011;20:338–43. https://doi.org/10.1016/j.yebeh.2010.11.016.
10. Viteva E. Impact of stigma on the quality of life of patients with refractory epilepsy. Seizure. 2013;22:64–9. https://doi.org/10.1016/j.seizure.2012.10.010.
11. Ba-Diop A, Marin B, Druet-Cabanac M, Ngoungou EB, Newton CR, Peux PM. Epidemiology, causes, and treatment of epilepsy in sub-Saharan Africa. Lancet Neurol. 2014;13:1029–44. https://doi.org/10.1016/S1474-4422(14)70114-0.
12. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW; Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883–90. https://doi.org/10.1111/j.1528-1167.2009.02481.x.
13. Ibinda F, Odermitt P, Kariki SM, et al. Magnitude and factors associated with nonadherence to antiepileptic drug treatment in Africa: A cross-sectional multisite study. Epilepsia Open. 2017;2:226–35. https://doi.org/10.1002/epid.12052.
14. Kariki SM, Matuja W, Akpalu A, et al. Clinical features, proximate causes, and consequences of active convulsive epilepsy in Africa. Epilepsia. 2014;55:76–85. https://doi.org/10.1111/epi.12392.
15. Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49:1491–503. https://doi.org/10.1111/j.1528-1167.2008.01693.x.
16. Wagner RG, Kabudula CW, Forsgren L, et al. Epilepsy care cascade, treatment gap and its determinants in rural South Africa. Seizure. 2020;80:175–80. https://doi.org/10.1016/j.seizure.2020.06.013.
17. Cameron A, Bansal A, Dua T, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia. 2012;53:962–9. https://doi.org/10.1111/j.1528-1167.2012.03446.x.
18. Cameron A, Roubos I, Even M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011;89:412–21. https://doi.org/10.2471/bht.1084327.
19. World Health Organization. Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2032. Discussion paper, 2021. Stelzlé D, Schmidt V, Keller L. Characteristics of People with Epilepsy and Neurocysticercosis in Three Eastern African Countries – a Pooled Analysis. PLOS NTD 2022; Currently under review.
20. Schmidt V, O’Hara MC, Ngowi B, et al. Taenia solium cysticercosis and taeniasis in urban settings: Epidemiological evidence from a health-center based study among people with epilepsy in Dar es Salaam. Tanzania PLoS Negl Trop Dis. 2019;13:e0007751. https://doi.org/10.1371/journal.pntd.0007751.
21. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522–30. https://doi.org/10.1111/epi.13670.
22. Winkler AS, Schaffert M, Schmutzhard E. The pattern of epilepsy in a rural African hospital – an approach adapted to local circumstances. Trop Doct. 2009;39:44–7. https://doi.org/10.1258/tropmed.2008.080557.
23. Owolabi LF, Adamu B, Jibo AM, et al. Prevalence of active epilepsy, life-time epilepsy prevalence, and burden of epilepsy in Sub-Saharan Africa from meta-analysis of door-to-door population-based surveys. Epilepsy Behav. 2020;103:106846. https://doi.org/10.1016/j.yebeh.2019.106846.
